Zanzalintinib and etoposide after high-dose chemo for germ cell tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a germ cell tumor (testicular, ovarian, or mediastinal) that has come back or not responded to treatment.
- You've already had cisplatin-based chemotherapy, and for the phase 2 part, you've completed high-dose chemotherapy and a stem cell transplant.
- Your last high-dose chemotherapy was within the past 16 weeks.
- You are at least 18 years old and in generally good health (able to do daily activities).
- Your blood counts and organ function (kidney, liver, heart) are within acceptable ranges.
- You are willing to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This trial tests a combination of two chemotherapy drugs—teniposide and cisplatin—for people who have just been diagnosed with a malignant germ cell tumor in the brain. The goal is to see if this treatment is safe and effective.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests a drug called zanzalintinib as a maintenance therapy to keep high-grade neuroendocrine tumors from growing after chemotherapy. It may be a good option if you've had success with chemotherapy and are ready for a treatment break.
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.